Welcome to our dedicated page for Rapt Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RAPT Therapeutics, Inc. (Nasdaq: RAPT) SEC filings page on Stock Titan provides access to the company’s official reports and disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage immunology-based biopharmaceutical company focused on inflammatory and immunological diseases, RAPT uses SEC filings to report financial results, capital-raising activities and other material corporate events.
Investors can review current and historical Form 8-K filings in which RAPT reports items such as quarterly and year-to-date financial results, underwritten public offerings of common stock, and changes to its board of directors and governance arrangements. For example, recent 8-K filings have furnished press releases detailing net losses, research and development and general and administrative expenses, cash and marketable securities balances, and the terms and expected proceeds of a public equity offering intended to fund operations into 2028 based on the company’s stated operating plans.
Beyond 8-Ks, RAPT’s broader SEC reporting (such as Forms 10-Q and 10-K, referenced in its press releases) contains more extensive discussions of risk factors, pipeline programs, clinical trial status and accounting policies. These periodic reports are important for understanding how the company describes its clinical-stage immunology-based business model, including programs like ozureprubart and other early-stage assets, as well as its assessment of capital needs and potential risks.
On Stock Titan, SEC filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as changes in operating expenses, financing transactions, and material clinical or regulatory disclosures described in attached press releases or narrative sections. Users can quickly scan these summaries before diving into the full text of a filing.
For those tracking executive and director matters, RAPT’s filings also include information on board appointments, committee assignments and compensation policies, as seen in governance-related 8-K disclosures. Together, these documents provide a structured record of how RAPT communicates its financial condition, capital structure and development progress to regulators and the market.
RAPT Therapeutics, Inc. has a Schedule 13G disclosure showing Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, beneficially own 951,613 shares of RAPT common stock, representing 5.75% of the outstanding class. The filing states these shares are held by funds and separately managed accounts under Nantahala's control and that none of the Reporting Persons possess sole voting or dispositive power; all voting and dispositive power is shared. The statement affirms the position was acquired and is held in the ordinary course of business and not for the purpose of influencing control of the issuer.
RAPT Therapeutics, Inc. Schedule 13G/A filed by Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments III, L.P. reports beneficial ownership tied to both directly held common stock and exercisable warrants. Redmile Group and Mr. Green report 1,765,303 shares beneficially owned (9.9% of the class) and RBI III reports 1,147,390 shares (6.5% of the class). The filings explain ownership counts after a 1-for-8 reverse stock split and include up to 1,134,617 shares that could be issued upon exercise of certain pre-funded warrants subject to a 9.99% beneficial ownership blocker.
The filing discloses that Redmile Group acts as investment manager to Redmile Funds and that Mr. Green may be deemed to beneficially own the reported securities as principal of Redmile Group. Each reporting person disclaims beneficial ownership except for any pecuniary interest. The statement certifies the holdings are not for the purpose of changing control.
RAPT Therapeutics director Scott Braunstein received a stock option grant on June 21, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 25,000 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 21, 2035
- Vesting schedule: Equal annual installments over three years from grant date
This equity compensation grant appears to be part of the company's standard director compensation program. The options were granted with direct ownership form, and the filing was submitted by attorney-in-fact Rodney Young on June 24, 2025. This transaction represents a new position for the director, as no prior holdings were reported in the filing.
RAPT Therapeutics has filed a Form 3 (Initial Statement of Beneficial Ownership) for newly appointed Director Scott Braunstein, effective June 21, 2025. The filing discloses that Mr. Braunstein currently holds no beneficial ownership of any securities in the company, either direct or indirect.
Key details from the filing:
- Position: Director (non-employee)
- Filing Status: Individual filing
- Business Address: 561 Eccles Avenue, South San Francisco, CA 94080
- No ownership of non-derivative securities reported
- No ownership of derivative securities (options, warrants, etc.) reported
The Form 3 was signed by Rodney Young as Attorney-in-Fact on June 24, 2025, fulfilling the SEC requirement for new insiders to report their initial securities ownership within 10 days of becoming an officer, director, or 10% owner.
RAPT Therapeutics Chief Medical Officer William Ho received a new stock option grant on June 20, 2025. The derivative securities transaction details include:
- Grant of 75,000 employee stock options
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly from June 20, 2025
This Form 4 filing, signed by attorney-in-fact Rodney Young, represents a standard equity compensation grant to a key executive officer. The ten-year option grant suggests a long-term retention strategy for the Chief Medical Officer position. The monthly vesting schedule over four years aligns with typical industry practices for executive compensation.